TIME |
HALL A |
09:30 – 11:00 |
ACUTE MYELOID LEUKEMIA |
Scientific Chair: İnci Alacacıoğlu (Dokuz Eylül University, Turkey), Hartmut Döhner (University of Ulm Germany) Molecular Heterogeneity and Clonal Evolution of AML: Lars Bullinger (Charité Universitätsmedizin Berlin, Germany) Combining New Agents with “3+7“ Chemotherapy in Fit Patients: Hartmut Döhner (University of Ulm, Germany) New Agents For The Treatment of Older Patients: Andrew Wei (Alfred Hospital, Melbourne, Australia)
|
11:00 – 11:30 |
BREAK |
11:30 – 13:00 |
CHRONIC LYMPHOCYTIC LEUKEMIA |
Scientific Chair: Fatih Demirkan (Dokuz Eylül University, Turkey), Michael Hallek (University Hospital of Cologne, Germany) State-of-the Art First Line Therapy of CLL: Michael Hallek (University Hospital of Cologne, Germany) Management of Relapsed CLL and Richter Transformation: Davide Rossi (Institute of Oncology Research, Switzerland) Modelling of Response Pattern and Cloned Evolution of CLL: Othman Al-Sawaf (University Hospital of Cologne, Germany) |
13:00 – 13:30 |
BREAK |
13:30 -14:15 |
SATELLITE SYMPOSIUM The Evolving Role of Venetoclax in the Era of Novel R/R CLL Therapies
Scientific Chair: Burhan Ferhanoğlu (Koç University, Turkey) Speaker: Michael Hallek (University Hospital of Cologne, Germany)
|
14:15 – 14:45 |
BREAK |
14:45- 16:15 |
HODGKIN LYMPHOMA |
Scientific Chair: Muhit Özcan (Ankara University, Turkey), Bastian von Tresckow (University Hospital Essen, Germany) Firstline Treatment of HL: Paul Bröckelmann (University Hospital of Cologne, Germany) Update on NLPHL: Dennis Eichenauer (University Hospital of Cologne, Germany) Relapsed and Refractory HL: Innovative Therapies: Bastian von Tresckow (University Hospital Essen , Germany) |
16:15 – 16:45 |
BREAK |
16:45 – 17:30 |
SATELLITE SYMPOSIUM
Optimizing Outcomes for Patients with CLL in 2021: Challenging the Genetics
Scientific Chair: Ahmet Muzaffer Demir (Trakya University, Turkey)
How Biology is Informing Treatment Decisions in Firstline CLL ?: Fatih Demirkan (Dokuz Eylül University, Turkey)
Breakthrough CLL Disease Control in Relapsed & Refractory Settings: Long Term Ibrutinib Outcomes: Önder Arslan (Ankara University, Turkey)
|
17:30 – 18:00 |
BREAK |
18:00 – 19:30 |
ACUTE LYMPHOBLASTIC LEUKEMIA |
Scientific Chair: Önder Arslan (Ankara University, Turkey), Dieter Hoelzer (Goethe University of Frankfurt, Germany) Immunotherapies in B-Lineage ALL: Dieter Hoelzer (Goethe University of Frankfurt, Germany) Current Status and Future Prospects in T-ALL: Nicolas Boissel (Hôpital Saint-Louis, France) Progress in Ph+/Ph-like ALL: Oliver Ottmann (Cardiff University, Wales) |
19:30 – 20:00 |
BREAK |
20:00 – 21:30 |
AGGRESSIVE LYMPHOMAS |
Scientific Chair: Burhan Ferhanoğlu (Koç University, Turkey), Martin Dreyling (Munich University, Germany) Primary CNS Lymphoma: Andres Ferreri (Vita-Salute San Raffaele University, Italy) Mantle Cell Lymphoma: Martin Dreyling (Munich University, Germany) CAR T-Cells in DLBCL: Marion Subklewe (Gene Center, Germany) |
21:30 – 21:45 |
BREAK |
21:45 – 22:00 |
Closing Remarks |